Close

CymaBay Therapeutics (CBAY) Announces Clinically Meaningful Data from MBX-8025 Phase 2 in HoFH

Go back to CymaBay Therapeutics (CBAY) Announces Clinically Meaningful Data from MBX-8025 Phase 2 in HoFH

CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia

March 17, 2016 4:01 PM EDT

NEWARK, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced top line results from its pilot Phase 2 clinical study of MBX-8025 in patients with homozygous familial hypercholesterolemia (HoFH).  The study demonstrated that the range of responses to MBX-8025 was broad, but that MBX-8025 provided a clinically meaningful reduction in low-density lipoprotein cholesterol (LDL-C) for a subset of patients. This is the first study to demonstrate the potential utility of a PPAR agonist in HoFH.  

This pilot study provides the first evidence that MBX-8025 has potential... More